Please use this identifier to cite or link to this item:
https://biore.bio.bg.ac.rs/handle/123456789/814
Title: | Design and in vitro biological evaluation of a novel organotin(IV) complex with 1-(4-carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione | Authors: | Pantelić, Nebojša D. Zmejkovski, Bojana B. Žižak, Željko Banjac, Nebojša R. Božić, Bojan Stanojković, Tatjana P. Kaluđerović, Goran N. |
Issue Date: | 1-Jan-2019 | Rank: | M22 | Journal: | Journal of Chemistry | Abstract: | © 2019 Nebojša D. Pantelić et al. A novel triphenyltin(IV) compound with 1-(4-carboxyphenyl)-3-ethyl-3-methylpyrrolidine-2,5-dione was synthesized and characterized by IR, NMR spectroscopy, mass spectrometry, and elemental analysis. In vitro anticancer activity of ligand precursor and synthesized organotin(IV) compound was determined against tumor cell lines: Human adenocarcinoma (HeLa), human myelogenous leukemia (K562), and human breast cancer (MDA-MB-453), using microculture tetrazolium test (MTT) assay. The results indicate that complex exhibited very high antiproliferative activity against all tested cell lines with IC50 values in the range of 0.22 to 0.53 μM. The highest activity organotin(IV) compound expressed against the HeLa cells (IC50 = 0.22 ± 0.04 μM). The ligand precursor did not show anticancer activity (IC50 > 200 μM). Furthermore, fluorescence microscopy analysis of HeLa cells reveal that organotin(IV) complex induced apoptosis as a mode of cell death, which is consistent with the increase of cells in the sub-G1 phase. |
URI: | https://biore.bio.bg.ac.rs/handle/123456789/814 | ISSN: | 2090-9063 | DOI: | 10.1155/2019/2905840 |
Appears in Collections: | Journal Article |
Files in This Item:
File | Description | Size | Format | Existing users please |
---|---|---|---|---|
6 Design and In Vitro Biological Evaluation of a Novel.pdf | 1.85 MB | Adobe PDF | Request a copy |
SCOPUSTM
Citations
19
checked on Nov 16, 2024
Page view(s)
6
checked on Nov 20, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.